Mesenchymal stem cell carriers enhance anti‑tumor efficacy of oncolytic virotherapy (Review)
- Authors:
- Xianyao Wang
- Xing Zhao
- Zhixu He
-
Affiliations: Center for Tissue Engineering and Stem Cell Research, Guizhou Medical University, Guiyang, Guizhou 550004, P.R. China, Key Laboratory of Adult Stem Cell Translational Research, Chinese Academy of Medical Sciences, Guiyang, Guizhou 550004, P.R. China - Published online on: January 28, 2021 https://doi.org/10.3892/ol.2021.12499
- Article Number: 238
-
Copyright: © Wang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.
This article is mentioned in:
Abstract
 |
 |
|
Hayes C: Cellular immunotherapies for cancer. Ir J Med Sci. Jul 1–2020.(Epub ahead of print). doi: 10.1007/s11845-020-02264-w. | |
|
Alard E, Butnariu AB, Grillo M, Kirkham C, Zinovkin DA, Newnham L, Macciochi J and Pranjol MZI: Advances in anti-cancer immunotherapy: Car-T cell, checkpoint inhibitors, dendritic cell vaccines, and oncolytic viruses, and emerging cellular and molecular targets. Cancers (Basel). 12:18262020. View Article : Google Scholar | |
|
Hemminki O, Dos Santos JM and Hemminki A: Oncolytic viruses for cancer immunotherapy. J Hematol Oncol. 13:842020. View Article : Google Scholar : PubMed/NCBI | |
|
Romero D: Immunotherapy: Oncolytic viruses prime antitumour immunity. Nat Rev Clin Oncol. 15:1352018. View Article : Google Scholar : PubMed/NCBI | |
|
Engeland CE and Bell JC: Introduction to oncolytic virotherapy. Methods Mol Biol. 2058:1–6. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Kolb EA, Sampson V, Stabley D, Walter A, Sol-Church K, Cripe T, Hingorani P, Ahern CH, Weigel BJ, Zwiebel J and Blaney SM: A phase I trial and viral clearance study of reovirus (Reolysin) in children with relapsed or refractory extra-cranial solid tumors: A children's oncology group phase I consortium report. Pediatr Blood Cancer. 62:751–758. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Hamid O, Ismail R and Puzanov I: Intratumoral immunotherapy-update 2019. Oncologist. 25:e423–e438. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Roy DG, Bell JC and Bourgeois-Daigneault MC: Magnetic targeting of oncolytic VSV-based therapies improves infection of tumor cells in the presence of virus-specific neutralizing antibodies in vitro. Biochem Biophys Res Commun. 526:641–646. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Schirrmacher V, van Gool S and Stuecker W: Breaking therapy resistance: An update on oncolytic newcastle disease virus for improvements of cancer therapy. Biomedicines. 7:662019. View Article : Google Scholar | |
|
Mahasa KJ, de Pillis L, Ouifki R, Eladdadi A, Maini P, Yoon AR and Yun CO: Mesenchymal stem cells used as carrier cells of oncolytic adenovirus results in enhanced oncolytic virotherapy. Sci Rep. 10:4252020. View Article : Google Scholar : PubMed/NCBI | |
|
Hadrys A, Sochanik A, McFadden G and Jazowiecka-Rakus J: Mesenchymal stem cells as carriers for systemic delivery of oncolytic viruses. Eur J Pharmacol. 874:1729912020. View Article : Google Scholar : PubMed/NCBI | |
|
Naseri Z, Oskuee RK, Forouzandeh-Moghadam M and Jaafari MR: Delivery of LNA-antimiR-142-3p by mesenchymal stem cells-derived exosomes to breast cancer stem cells reduces tumorigenicity. Stem Cell Rev Rep. 16:541–556. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Altaner C and Altanerova U: Mesenchymal stem cell exosome-mediated prodrug gene therapy for cancer. Methods Mol Biol. 1895:75–85. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Kostadinova M and Mourdjeva M: Potential of mesenchymal stem cells in anti-cancer therapies. Curr Stem Cell Res Ther. 15:482–491. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Spaggiari GM, Capobianco A, Abdelrazik H, Becchetti F, Mingari MC and Moretta L: Mesenchymal stem cells inhibit natural killer-cell proliferation, cytotoxicity, and cytokine production: Role of indoleamine 2,3-dioxygenase and prostaglandin E2. Blood. 111:1327–1333. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Jiang XX, Zhang Y, Liu B, Zhang SX, Wu Y, Yu XD and Mao N: Human mesenchymal stem cells inhibit differentiation and function of monocyte-derived dendritic cells. Blood. 105:4120–4126. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Lei J, Jacobus EJ, Taverner WK, Fisher KD, Hemmi S, West K, Slater L, Lilley F, Brown A, Champion B, et al: Expression of human CD46 and trans-complementation by murine adenovirus 1 fails to allow productive infection by a group B oncolytic adenovirus in murine cancer cells. J Immunother Cancer. 6:552018. View Article : Google Scholar : PubMed/NCBI | |
|
Koehler M, Aravamudhan P, Guzman-Cardozo C, Dumitru AC, Yang J, Gargiulo S, Soumillion P, Dermody TS and Alsteens D: Glycan-mediated enhancement of reovirus receptor binding. Nat Commun. 10:44602019. View Article : Google Scholar : PubMed/NCBI | |
|
Phillips MB, Stuart JD, Rodriguez Stewart RM, Berry JT, Mainou BA and Boehme KW: Current understanding of reovirus oncolysis mechanisms. Oncolytic Virother. 7:53–63. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Sakurai F, Inoue S, Kaminade T, Hotani T, Katayama Y, Hosoyamada E, Terasawa Y, Tachibana M and Mizuguchi H: Cationic liposome-mediated delivery of reovirus enhances the tumor cell-killing efficiencies of reovirus in reovirus-resistant tumor cells. Int J Pharm. 524:238–247. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Mahalingam D, Goel S, Aparo S, Patel Arora S, Noronha N, Tran H, Chakrabarty R, Selvaggi G, Gutierrez A, Coffey M, et al: A phase II study of pelareorep (REOLYSIN(R)) in combination with gemcitabine for patients with advanced pancreatic adenocarcinoma. Cancers (Basel). 10:1602018. View Article : Google Scholar | |
|
Jonker DJ, Tang PA, Kennecke H, Welch SA, Cripps MC, Asmis T, Chalchal H, Tomiak A, Lim H, Ko YJ, et al: A randomized phase II study of FOLFOX6/bevacizumab with or without pelareorep in patients with metastatic colorectal cancer: IND.210, a canadian cancer trials group trial. Clin Colorectal Cancer. 17:231–239 e7. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Davola ME and Mossman KL: Oncolytic viruses: How ‘lytic’ must they be for therapeutic efficacy? Oncoimmunology. 8:e15815282019. View Article : Google Scholar : PubMed/NCBI | |
|
Luo Y, Lin C, Zou Y, Ju F, Ren W, Lin Y, Wang Y, Huang X, Liu H, Yu Z, et al: Tumor-targeting oncolytic virus elicits potent immunotherapeutic vaccine responses to tumor antigens. Oncoimmunology. 9:17261682020. View Article : Google Scholar : PubMed/NCBI | |
|
Pidelaserra-Marti G and Engeland CE: Mechanisms of measles virus oncolytic immunotherapy. Cytokine Growth Factor Rev. 56:28–38. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Pol JG, Bridle BW and Lichty BD: Detection of tumor antigen-specific T-cell responses after oncolytic vaccination. Methods Mol Biol. 2058:191–211. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Keshavarz M, Solaymani-Mohammadi F, Miri SM and Ghaemi A: Oncolytic paramyxoviruses-induced autophagy; a prudent weapon for cancer therapy. J Biomed Sci. 26:482019. View Article : Google Scholar : PubMed/NCBI | |
|
Bommareddy PK, Zloza A, Rabkin SD and Kaufman HL: Oncolytic virus immunotherapy induces immunogenic cell death and overcomes STING deficiency in melanoma. Oncoimmunology. 8:15918752019. View Article : Google Scholar : PubMed/NCBI | |
|
Ma J, Ramachandran M, Jin C, Quijano-Rubio C, Martikainen M, Yu D and Essand M: Characterization of virus-mediated immunogenic cancer cell death and the consequences for oncolytic virus-based immunotherapy of cancer. Cell Death Dis. 11:482020. View Article : Google Scholar : PubMed/NCBI | |
|
Wang X, Shao X, Gu L, Jiang K, Wang S, Chen J, Fang J, Guo X, Yuan M, Shi J, et al: Targeting STAT3 enhances NDV-induced immunogenic cell death in prostate cancer cells. J Cell Mol Med. 24:4286–4297. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Shao X, Wang X, Guo X, Jiang K, Ye T, Chen J, Fang J, Gu L, Wang S, Zhang G, et al: STAT3 contributes to oncolytic newcastle disease virus-induced immunogenic cell death in melanoma cells. Front Oncol. 9:4362019. View Article : Google Scholar : PubMed/NCBI | |
|
Xu Q, Rangaswamy US, Wang W, Robbins SH, Harper J, Jin H and Cheng X: Evaluation of newcastle disease virus mediated dendritic cell activation and cross-priming tumor-specific immune responses ex vivo. Int J Cancer. 146:531–541. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Garg AD and Agostinis P: Cell death and immunity in cancer: From danger signals to mimicry of pathogen defense responses. Immunol Rev. 280:126–148. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Jiang H and Fueyo J: Healing after death: Antitumor immunity induced by oncolytic adenoviral therapy. Oncoimmunology. 3:e9478722014. View Article : Google Scholar : PubMed/NCBI | |
|
Kepp O, Senovilla L, Vitale I, Vacchelli E, Adjemian S, Agostinis P, Apetoh L, Aranda F, Barnaba V, Bloy N, et al: Consensus guidelines for the detection of immunogenic cell death. Oncoimmunology. 3:e9556912014. View Article : Google Scholar : PubMed/NCBI | |
|
Garg AD, Galluzzi L, Apetoh L, Baert T, Birge RB, Bravo-San Pedro JM, Breckpot K, Brough D, Chaurio R, Cirone M, et al: Molecular and translational classifications of DAMPs in immunogenic cell death. Front Immunol. 6:5882015. View Article : Google Scholar : PubMed/NCBI | |
|
Das K, Urbiola C, Spiesschaert B, Mueller P and Wollmann G: Analysis of immunological treatment effects of virotherapy in tumor tissue. Methods Mol Biol. 2058:155–177. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Reale A, Vitiello A, Conciatori V, Parolin C, Calistri A and Palu G: Perspectives on immunotherapy via oncolytic viruses. Infect Agent Cancer. 14:52019. View Article : Google Scholar : PubMed/NCBI | |
|
Sobol PT, Boudreau JE, Stephenson K, Wan Y, Lichty BD and Mossman KL: Adaptive antiviral immunity is a determinant of the therapeutic success of oncolytic virotherapy. Mol Ther. 19:335–344. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Gujar S, Pol JG, Kim Y, Lee PW and Kroemer G: Antitumor benefits of antiviral immunity: An underappreciated aspect of oncolytic virotherapies. Trends Immunol. 39:209–221. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Ledford H: Cancer-fighting viruses win approval. Nature. 526:622–623. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
O'Donoghue C, Doepker MP and Zager JS: Talimogene laherparepvec: Overview, combination therapy and current practices. Melanoma Manag. 3:267–272. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Sunshine JC, Sosman J, Shetty A and Choi JN: Successful treatment of in-transit metastatic melanoma in a renal transplant patient with combination T-VEC/Imiquimod immunotherapy. J Immunother. 43:149–152. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Masoud SJ, Hu JB, Beasley GM, Stewart JH IV and Mosca PJ: Efficacy of talimogene laherparepvec (T-VEC) therapy in patients with in-transit melanoma metastasis decreases with increasing lesion size. Ann Surg Oncol. 26:4633–4641. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Howard F and Muthana M: Designer nanocarriers for navigating the systemic delivery of oncolytic viruses. Nanomedicine (Lond). 15:93–110. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Phan M, Watson MF, Alain T and Diallo JS: Oncolytic viruses on drugs: Achieving higher therapeutic efficacy. ACS Infect Dis. 4:1448–1467. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Rosewell Shaw A and Suzuki M: Oncolytic viruses partner with T-cell therapy for solid tumor treatment. Front Immunol. 9:21032018. View Article : Google Scholar : PubMed/NCBI | |
|
Hwang CC, Igase M, Sakurai M, Haraguchi T, Tani K, Itamoto K, Shimokawa T, Nakaichi M, Nemoto Y, Noguchi S, et al: Oncolytic reovirus therapy: Pilot study in dogs with spontaneously occurring tumours. Vet Comp Oncol. 16:229–238. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Mok DZL and Chan KR: The effects of pre-existing antibodies on live-attenuated viral vaccines. Viruses. 12:5202020. View Article : Google Scholar | |
|
Harrington K, Freeman DJ, Kelly B, Harper J and Soria JC: Optimizing oncolytic virotherapy in cancer treatment. Nat Rev Drug Discov. 18:689–706. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Naji A, Eitoku M, Favier B, Deschaseaux F, Rouas-Freiss N and Suganuma N: Biological functions of mesenchymal stem cells and clinical implications. Cell Mol Life Sci. 76:3323–3348. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Volarevic V, Markovic BS, Gazdic M, Volarevic A, Jovicic N, Arsenijevic N, Armstrong L, Djonov V, Lako M and Stojkovic M: Ethical and safety issues of stem cell-based therapy. Int J Med Sci. 15:36–45. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Dominici M, Le Blanc K, Mueller I, Slaper-Cortenbach I, Marini F, Krause D, Deans R, Keating A, Prockop DJ and Horwitz E: Minimal criteria for defining multipotent mesenchymal stromal cells. The international society for cellular therapy position statement. Cytotherapy. 8:315–317. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Salmasi Z, Hashemi M, Mahdipour E, Nourani H, Abnous K and Ramezani M: Mesenchymal stem cells engineered by modified polyethylenimine polymer for targeted cancer gene therapy, in vitro and in vivo. Biotechnol Prog. 36:e30252020. View Article : Google Scholar : PubMed/NCBI | |
|
Yoon AR, Hong J, Li Y, Shin HC, Lee H, Kim HS and Yun CO: Mesenchymal stem cell-mediated delivery of an oncolytic adenovirus enhances antitumor efficacy in hepatocellular carcinoma. Cancer Res. 79:4503–4514. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Vangala G, Imhoff FM, Squires CML, Cridge AG and Baird SK: Mesenchymal stem cell homing towards cancer cells is increased by enzyme activity of cathepsin D. Exp Cell Res. 383:1114942019. View Article : Google Scholar : PubMed/NCBI | |
|
Kwon S, Yoo KH, Sym SJ and Khang D: Mesenchymal stem cell therapy assisted by nanotechnology: A possible combinational treatment for brain tumor and central nerve regeneration. Int J Nanomedicine. 14:5925–5942. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Thomas JG, Parker Kerrigan BC, Hossain A, Gumin J, Shinojima N, Nwajei F, Ezhilarasan R, Love P, Sulman EP and Lang FF: Ionizing radiation augments glioma tropism of mesenchymal stem cells. J Neurosurg. 128:287–295. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Choi SA, Lee JY, Kwon SE, Wang KC, Phi JH, Choi JW, Jin X, Lim JY, Kim H and Kim SK: Human adipose tissue-derived mesenchymal stem cells target brain tumor-initiating cells. PLoS One. 10:e01292922015. View Article : Google Scholar : PubMed/NCBI | |
|
Verdelli C, Vaira V and Corbetta S: Parathyroid tumor microenvironment. Adv Exp Med Biol. 1226:37–50. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Karagiannis K, Proklou A, Tsitoura E, Lasithiotaki I, Kalpadaki C, Moraitaki D, Sperelakis I, Kontakis G, Antoniou KM and Tzanakis N: Impaired mRNA expression of the migration related chemokine receptor CXCR4 in mesenchymal stem cells of COPD patients. Int J Inflam. 2017:60894252017. View Article : Google Scholar : PubMed/NCBI | |
|
Armakolas A, Dimakakos A, Loukogiannaki C, Armakolas N, Antonopoulos A, Florou C, Tsioli P, Papageorgiou E, Alexandrou TP, Stathaki M, et al: IL-6 is associated to IGF-1Ec upregulation and Ec peptide secretion, from prostate tumors. Mol Med. 24:62018. View Article : Google Scholar : PubMed/NCBI | |
|
Lejmi E, Perriraz N, Clement S, Morel P, Baertschiger R, Christofilopoulos P, Meier R, Bosco D, Buhler LH and Gonelle-Gispert C: Inflammatory chemokines MIP-1δ and MIP-3α are involved in the migration of multipotent mesenchymal stromal cells induced by hepatoma cells. Stem Cells Dev. 24:1223–1235. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Pavon LF, Sibov TT, de Souza AV, da Cruz EF, Malheiros SM, Cabral FR, de Souza JG, Boufleur P, de Oliveira DM, de Toledo SR, et al: Tropism of mesenchymal stem cell toward CD133+ stem cell of glioblastoma in vitro and promote tumor proliferation in vivo. Stem Cell Res Ther. 9:3102018. View Article : Google Scholar : PubMed/NCBI | |
|
Ramirez M, Garcia-Castro J, Melen GJ, Gonzalez-Murillo A and Franco-Luzon L: Patient-derived mesenchymal stem cells as delivery vehicles for oncolytic virotherapy: Novel state-of-the-art technology. Oncolytic Virother. 4:149–155. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Kaczorowski A, Hammer K, Liu L, Villhauer S, Nwaeburu C, Fan P, Zhao Z, Gladkich J, Gross W, Nettelbeck DM and Herr I: Delivery of improved oncolytic adenoviruses by mesenchymal stromal cells for elimination of tumorigenic pancreatic cancer cells. Oncotarget. 7:9046–9059. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Mehler VJ, Burns C and Moore ML: Concise review: Exploring immunomodulatory features of mesenchymal stromal cells in humanized mouse models. Stem Cells. 37:298–305. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Gao F, Chiu SM, Motan DA, Zhang Z, Chen L, Ji HL, Tse HF, Fu QL and Lian Q: Mesenchymal stem cells and immunomodulation: Current status and future prospects. Cell Death Dis. 7:e20622016. View Article : Google Scholar : PubMed/NCBI | |
|
Abbasi-Kangevari M, Ghamari SH, Safaeinejad F, Bahrami S and Niknejad H: Potential therapeutic features of human amniotic mesenchymal stem cells in multiple sclerosis: Immunomodulation, inflammation suppression, angiogenesis promotion, oxidative stress inhibition, neurogenesis induction, MMPs regulation, and remyelination stimulation. Front Immunol. 10:2382019. View Article : Google Scholar : PubMed/NCBI | |
|
Ma ZJ, Wang YH, Li ZG, Wang Y, Li BY, Kang HY and Wu XY: Immunosuppressive effect of exosomes from mesenchymal stromal cells in defined medium on experimental colitis. Int J Stem Cells. 12:440–448. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Carreras-Planella L, Monguio-Tortajada M, Borras FE and Franquesa M: Immunomodulatory effect of MSC on B cells is independent of secreted extracellular vesicles. Front Immunol. 10:12882019. View Article : Google Scholar : PubMed/NCBI | |
|
Wilson A, Chee M, Butler P and Boyd AS: Isolation and characterisation of human adipose-derived stem cells. Methods Mol Biol. 1899:3–13. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Zhang F, Wang C, Wen X, Chen Y, Mao R, Cui D, Li L, Liu J, Chen Y, Cheng J and Lu Y: Mesenchymal stem cells alleviate rat diabetic nephropathy by suppressing CD103+ DCs-mediated CD8+ T cell responses. J Cell Mol Med. 24:5817–5831. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Haddad R and Saldanha-Araujo F: Mechanisms of T-cell immunosuppression by mesenchymal stromal cells: What do we know so far? Biomed Res Int. 2014:2168062014. View Article : Google Scholar : PubMed/NCBI | |
|
Rozenberg A, Rezk A, Boivin MN, Darlington PJ, Nyirenda M, Li R, Jalili F, Winer R, Artsy EA, Uccelli A, et al: Human mesenchymal stem cells impact Th17 and Th1 responses through a prostaglandin E2 and myeloid-dependent mechanism. Stem Cells Transl Med. 5:1506–1514. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Khare D, Or R, Resnick I, Barkatz C, Almogi-Hazan O and Avni B: Mesenchymal stromal cell-derived exosomes affect mRNA expression and function of B-lymphocytes. Front Immunol. 9:30532018. View Article : Google Scholar : PubMed/NCBI | |
|
Corcione A, Benvenuto F, Ferretti E, Giunti D, Cappiello V, Cazzanti F, Risso M, Gualandi F, Mancardi GL, Pistoia V and Uccelli A: Human mesenchymal stem cells modulate B-cell functions. Blood. 107:367–372. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Rezaei Kahmini F, Shahgaldi S and Moazzeni SM: Mesenchymal stem cells alter the frequency and cytokine profile of natural killer cells in abortion-prone mice. J Cell Physiol. 235:7214–7223. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Xu LL, Fu HX, Zhang JM, Feng FE, Wang QM, Zhu XL, Xue J, Wang CC, Chen Q, Liu X, et al: Impaired function of bone marrow mesenchymal stem cells from immune thrombocytopenia patients in inducing regulatory dendritic cell differentiation through the Notch-1/Jagged-1 signaling pathway. Stem Cells Dev. 26:1648–1661. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Liu Q, Zheng H, Chen X, Peng Y, Huang W, Li X, Li G, Xia W, Sun Q and Xiang AP: Human mesenchymal stromal cells enhance the immunomodulatory function of CD8(+)CD28(−) regulatory T cells. Cell Mol Immunol. 12:708–718. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
El Omar R, Xiong Y, Dostert G, Louis H, Gentils M, Menu P, Stoltz JF, Velot E and Decot V: Immunomodulation of endothelial differentiated mesenchymal stromal cells: Impact on T and NK cells. Immunol Cell Biol. 94:342–356. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Cho KA, Lee JK, Kim YH, Park M, Woo SY and Ryu KH: Mesenchymal stem cells ameliorate B-cell-mediated immune responses and increase IL-10-expressing regulatory B cells in an EBI3-dependent manner. Cell Mol Immunol. 14:895–908. 2017. View Article : Google Scholar | |
|
Liu X, Qu X, Chen Y, Liao L, Cheng K, Shao C, Zenke M, Keating A and Zhao RC: Mesenchymal stem/stromal cells induce the generation of novel IL-10-dependent regulatory dendritic cells by SOCS3 activation. J Immunol. 189:1182–1192. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Ahmed AU, Rolle CE, Tyler MA, Han Y, Sengupta S, Wainwright DA, Balyasnikova IV, Ulasov IV and Lesniak MS: Bone marrow mesenchymal stem cells loaded with an oncolytic adenovirus suppress the anti-adenoviral immune response in the cotton rat model. Mol Ther. 18:1846–1856. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Atiya H, Frisbie L, Pressimone C and Coffman L: Mesenchymal stem cells in the tumor microenvironment. Adv Exp Med Biol. 1234:31–42. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Cai C, Hou L, Zhang J, Zhao D, Wang Z, Hu H, He J, Guan W and Ma Y: The inhibitory effect of mesenchymal stem cells with rAd-NK4 on liver cancer. Appl Biochem Biotechnol. 183:444–459. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Fathi E, Sanaat Z and Farahzadi R: Mesenchymal stem cells in acute myeloid leukemia: A focus on mechanisms involved and therapeutic concepts. Blood Res. 54:165–174. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
El-Khadragy MF, Nabil HM, Hassan BN, Tohamy AA, Waaer HF, Yehia HM, Alharbi AM and Moneim AEA: Bone marrow cell therapy on 1,2-Dimethylhydrazine (DMH)-induced colon cancer in rats. Cell Physiol Biochem. 45:1072–1083. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Morales-Molina A, Gambera S, Cejalvo T, Moreno R, Rodriguez-Milla MA, Perise-Barrios AJ and Garcia-Castro J: Antitumor virotherapy using syngeneic or allogeneic mesenchymal stem cell carriers induces systemic immune response and intratumoral leukocyte infiltration in mice. Cancer Immunol Immunother. 67:1589–1602. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Ruano D, Lopez-Martin JA, Moreno L, Lassaletta A, Bautista F, Andion M, Hernandez C, Gonzalez-Murillo A, Melen G, Alemany R, et al: First-in-human, first-in-child trial of autologous MSCs carrying the oncolytic virus Icovir-5 in patients with advanced tumors. Mol Ther. 28:1033–1042. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Rincon E, Cejalvo T, Kanojia D, Alfranca A, Rodriguez-Milla MA, Gil Hoyos RA, Han Y, Zhang L, Alemany R, Lesniak MS and García-Castro J: Mesenchymal stem cell carriers enhance antitumor efficacy of oncolytic adenoviruses in an immunocompetent mouse model. Oncotarget. 8:45415–45431. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Banijamali RS, Soleimanjahi H, Soudi S, Karimi H, Abdoli A, Seyed Khorrami SM and Zandi K: Kinetics of oncolytic reovirus T3D replication and growth pattern in mesenchymal stem cells. Cell J. 22:283–292. 2020.PubMed/NCBI | |
|
Keshavarz M, Ebrahimzadeh MS, Miri SM, Dianat-Moghadam H, Ghorbanhosseini SS, Mohebbi SR, Keyvani H and Ghaemi A: Oncolytic newcastle disease virus delivered by mesenchymal stem cells-engineered system enhances the therapeutic effects altering tumor microenvironment. Virol J. 17:642020. View Article : Google Scholar : PubMed/NCBI | |
|
Hai C, Jin YM, Jin WB, Han ZZ, Cui MN, Piao XZ, Shen XH, Zhang SN and Sun HH: Application of mesenchymal stem cells as a vehicle to deliver replication-competent adenovirus for treating malignant glioma. Chin J Cancer. 31:233–240. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Du W, Seah I, Bougazzoul O, Choi G, Meeth K, Bosenberg MW, Wakimoto H, Fisher D and Shah K: Stem cell-released oncolytic herpes simplex virus has therapeutic efficacy in brain metastatic melanomas. Proc Natl Acad Sci USA. 114:E6157–E6165. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Ong HT, Federspiel MJ, Guo CM, Ooi LL, Russell SJ, Peng KW and Hui KM: Systemically delivered measles virus-infected mesenchymal stem cells can evade host immunity to inhibit liver cancer growth. J Hepatol. 59:999–1006. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Castleton A, Dey A, Beaton B, Patel B, Aucher A, Davis DM and Fielding AK: Human mesenchymal stromal cells deliver systemic oncolytic measles virus to treat acute lymphoblastic leukemia in the presence of humoral immunity. Blood. 123:1327–1335. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Hammer K, Kazcorowski A, Liu L, Behr M, Schemmer P, Herr I and Nettelbeck DM: Engineered adenoviruses combine enhanced oncolysis with improved virus production by mesenchymal stromal carrier cells. Int J Cancer. 137:978–990. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Kazimirsky G, Jiang W, Slavin S, Ziv-Av A and Brodie C: Mesenchymal stem cells enhance the oncolytic effect of newcastle disease virus in glioma cells and glioma stem cells via the secretion of TRAIL. Stem Cell Res Ther. 7:1492016. View Article : Google Scholar : PubMed/NCBI | |
|
Melen GJ, Franco-Luzon L, Ruano D, Gonzalez-Murillo A, Alfranca A, Casco F, Lassaletta A, Alonso M, Madero L, Alemany R, et al: Influence of carrier cells on the clinical outcome of children with neuroblastoma treated with high dose of oncolytic adenovirus delivered in mesenchymal stem cells. Cancer Lett. 371:161–170. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Leoni V, Gatta V, Palladini A, Nicoletti G, Ranieri D, Dall'Ora M, Grosso V, Rossi M, Alviano F, Bonsi L, et al: Systemic delivery of HER2-retargeted oncolytic-HSV by mesenchymal stromal cells protects from lung and brain metastases. Oncotarget. 6:34774–34787. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Hoyos V, Del Bufalo F, Yagyu S, Ando M, Dotti G, Suzuki M, Bouchier-Hayes L, Alemany R and Brenner MK: Mesenchymal stromal cells for linked delivery of oncolytic and apoptotic adenoviruses to non-small-cell lung cancers. Mol Ther. 23:1497–1506. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Franco-Luzon L, Gonzalez-Murillo A, Alcantara-Sanchez C, Garcia-Garcia L, Tabasi M, Huertas AL, Chesler L and Ramirez M: Systemic oncolytic adenovirus delivered in mesenchymal carrier cells modulate tumor infiltrating immune cells and tumor microenvironment in mice with neuroblastoma. Oncotarget. 11:347–361. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Morales-Molina A, Rodriguez-Milla MA, Gimenez-Sanchez A, Perise-Barrios AJ and Garcia-Castro J: Cellular virotherapy increases tumor-infiltrating lymphocytes (TIL) and decreases their PD-1+ subsets in mouse immunocompetent models. Cancers (Basel). 12:19202020. View Article : Google Scholar | |
|
Mader EK, Maeyama Y, Lin Y, Butler GW, Russell HM, Galanis E, Russell SJ, Dietz AB and Peng KW: Mesenchymal stem cell carriers protect oncolytic measles viruses from antibody neutralization in an orthotopic ovarian cancer therapy model. Clin Cancer Res. 15:7246–7255. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Hakkarainen T, Sarkioja M, Lehenkari P, Miettinen S, Ylikomi T, Suuronen R, Desmond RA, Kanerva A and Hemminki A: Human mesenchymal stem cells lack tumor tropism but enhance the antitumor activity of oncolytic adenoviruses in orthotopic lung and breast tumors. Hum Gene Ther. 18:627–641. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Ocansey DKW, Pei B, Yan Y, Qian H, Zhang X, Xu W and Mao F: Improved therapeutics of modified mesenchymal stem cells: An update. J Transl Med. 18:422020. View Article : Google Scholar : PubMed/NCBI | |
|
Najafi M, Goradel NH, Farhood B, Salehi E, Solhjoo S, Toolee H, Kharazinejad E and Mortezaee K: Tumor microenvironment: Interactions and therapy. J Cell Physiol. 234:5700–5721. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Oh CM, Chon HJ and Kim C: Combination immunotherapy using oncolytic virus for the treatment of advanced solid tumors. Int J Mol Sci. 21:77432020. View Article : Google Scholar | |
|
Sostoa J, Dutoit V and Migliorini D: Oncolytic viruses as a platform for the treatment of malignant brain tumors. Int J Mol Sci. 21:74492020. View Article : Google Scholar | |
|
Sivanandam V, LaRocca CJ, Chen NG, Fong Y and Warner SG: Oncolytic viruses and immune checkpoint inhibition: The best of both worlds. Mol Ther Oncolytics. 13:93–106. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Heinio C, Havunen R, Santos J, de Lint K, Cervera-Carrascon V, Kanerva A and Hemminki A: TNFα and IL2 encoding oncolytic adenovirus activates pathogen and danger-associated immunological signaling. Cells. 9:7982020. View Article : Google Scholar | |
|
Ribas A, Dummer R, Puzanov I, VanderWalde A, Andtbacka RHI, Michielin O, Olszanski AJ, Malvehy J, Cebon J, Fernandez E, et al: Oncolytic virotherapy promotes intratumoral T cell infiltration and improves Anti-PD-1 immunotherapy. Cell. 174:1031–1032. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Sun L, Funchain P, Song JM, Rayman P, Tannenbaum C, Ko J, McNamara M, Marcela Diaz-Montero C and Gastman B: Talimogene laherparepvec combined with anti-PD-1 based immunotherapy for unresectable stage III–IV melanoma: A case series. J Immunother Cancer. 6:362018. View Article : Google Scholar : PubMed/NCBI |
